Clinical and experimental evidence supports that chronic oxidative stress is a primary contributing factor to numerous retinal degenerative diseases, such as age-related macular degeneration (AMD).
Potential of melatonin to treat or prevent age-related macular degeneration through stimulation of telomerase activity
I suggest that melatonin therapy as pharmacologic agents and/or melatonin-rich foods, especially in AMD patients with measured low serum melatonin levels or high risk patients would be possibly an alternative approach to prevent and/or treat AMD.
Melatonin Metabolites Protect Human Retinal Pigment Epithelial Cells from Death Caused by Oxidative Stress
“It was concluded that these melatonin metabolites might be useful in treating many retinal conditions linked to the oxidative stress-induced damage.”
Melatonin cytoprotective properties may have practical implications in the treatment of ocular diseases, like glaucoma and age-related macular degeneration.
Melatonin, being an efficient antioxidant with antinitridergic properties, has a promising role in the treatment and management of glaucoma.
Current evidence suggests that melatonin may act as a protective agent in ocular conditions such as photo-keratitis, cataract, glaucoma and retinopathy.
The majority had reduced pathologic macular changes. We conclude that the daily use of 3 mg melatonin seems to protect the retina and to delay macular degeneration. No significant side effects were observed…
Study finds that Melatonin also offers a promising role in the safe treatment and management of Glaucoma
“Data indicates that melatonin, being an efficient antioxidant with antinitridergic properties, has a promising role in the treatment and management of glaucoma.”
Current research has revealed that the topical application of specific nutrients to the eyes can prevent and even reverse the progression of eye pressure and glaucoma severity for thousands of aging individuals.